IMMUNIC INC
Immunic Inc (IMUX) is a small-cap biotechnology company with a market capitalisation of about $81.12 million. As a company in the biotech space, its prospects tend to be driven by clinical results, regulatory decisions, partnerships and financing activity rather than steady earnings. That makes IMUX inherently more speculative and often more volatile than larger, diversified firms. Investors should focus on the company’s latest regulatory filings, press releases and cash runway, since small biotechs frequently need to raise capital to fund development. Potential upside may come from positive trial readouts or strategic collaborations, while downside risks include trial failures, regulatory setbacks and dilution from new funding. This summary is educational only; it is not personal financial advice. Consider your risk tolerance and consult an authorised financial professional before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Immunic Inc.'s stock, believing it has good potential for growth.
Financial Health
Immune Inc shows strong cash flow and solid book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IMUX
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Potential Growth Drivers
Clinical readouts, approvals or partnerships can materially change outlook, though these events are uncertain and can go either way.
Catalysts To Watch
Upcoming trial milestones or financing announcements are common catalysts; they may boost momentum or increase volatility.
Market & Funding Context
Small-cap biotechs often need fresh capital to progress programmes — check cash runway and dilution risk before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
